EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Differential Efficacy of Alpelisib by PIK3CA Mutation Site in Head and Neck Squamous Cell Carcinoma: An Analysis from the KCSG HN 15-16 TRIUMPH Trial

Kyoo Hyun Kim, Shinwon Hwang, Min Kyoung Kim, Keon-Uk Park, Tak Yun, Keun-Wook Lee, Joo Hang Kim, Bhumsuk Keam, Byoung Chul Cho, So Yeon Oh, Sang Hee Cho, Sangwoo Kim und 3 weitere

Cancer Research and Treatment · 15.10.2025 · 57 (4) · 968-980

DOI: 10.4143/crt.2024.1195 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Research and Treatment, erschienen am 15.10.2025. Verfasst von Kyoo Hyun Kim und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Class I Phosphatidylinositol 3-Kinases, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Mutation. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Ministry of Health and Welfare, National Research Foundation of Korea, Ministry of Science and ICT.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The TRIUMPH trial was a biomarker-driven umbrella trial for patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). This analysis focuses on the PIK3CAα (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) inhibitor alpelisib (arm 1) in patients with phosphoinositide 3-kinase (PI3K) pathway alterations.Materials and Methods Patients with PI3K pathway altered tumors were enrolled in the alpelisib arm of the TRIUMPH study. We conducted a detailed analysis of the correlation between PI3K pathway mutations and treatment outcomes including disease control rate, overall survival (OS), and progression-free survival (PFS).

Results

From October 2017 and August 2020, 203 were enrolled, with 42 treated with alpelisib. Response evaluation was possible for 33 patients. Genomic profiles revealed PIK3CA amplifications in 26.2%, and point mutations in E542K (26.2%), E545K (23.8%), and H1047R (9.5%). Neither PIK3CA amplification nor co-occurring TP53 mutations had a notable influence on alpelisib response or survival outcomes. Although the overall response rates were similar between helical domain mutations (E542, E545) and kinase domain mutation (H1047), patients with H1047 mutation exhibited significantly poorer PFS compared to those with non-H1047 PIK3CA alterations (1.6 vs. 7.3 months, p=0.017). OS in patients with H1047 kinase domain mutation showed a trend toward being shorter compared to others, though this difference did not reach statistical significance.

Conclusion

Alpelisib showed differential efficacy based on PI3K pathway alterations in patients with R/M HNSCC and was well-tolerated. These findings suggest the usefulness of next-generation sequencing testing-based decision-making when using the targeted agents in R/M HNSCC. We need to confirm results in larger cohorts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Class I Phosphatidylinositol 3-KinasesSquamous Cell Carcinoma of Head and NeckHead and Neck NeoplasmsMutationThiazolesHumansFemaleMaleMiddle AgedAgedAdultBiomarkers, Tumor

Stichwörter der Autor:innen

AlpelisibNGSPI3K pathwayPrecision medicineSquamous cell carcinoma of head and neckUmbrella trial

Substanzen

Class I Phosphatidylinositol 3-KinasesPIK3CA protein, humanAlpelisibThiazolesBiomarkers, Tumor

Autor:innen und Institutionen

  • Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
  • Department of Dermatology, Yonsei University College of Medicine, Seoul, Korea.
  • Division of Hematology-Oncology, Department of Internal Medicine, Yeungnam University Hospital, Yeungnam University College of Medicine, Daegu, Korea.
  • Department of Internal Medicine, Keimyung University Dongsan Medical Center, Daegu, Korea.
  • Rare Cancers Clinic, Center for Specific Organs Center, National Cancer Center, Goyang, Korea.
  • Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.

Förderung

  • Ministry of Health and Welfare
  • National Research Foundation of Korea
  • Ministry of Science and ICT

Zitieren

APA

Kim, K. H., Hwang, S., Kim, M. K., Park, K. U., Yun, T., Lee, K. W., Kim, J. H., Keam, B., Cho, B. C., Oh, S. Y., Cho, S. H., Kim, S., Kim, S. B., Hong, M. H., & Kim, H. R. (2025). Differential Efficacy of Alpelisib by PIK3CA Mutation Site in Head and Neck Squamous Cell Carcinoma: An Analysis from the KCSG HN 15-16 TRIUMPH Trial. Cancer Research and Treatment, 57(4), 968-980. https://doi.org/10.4143/crt.2024.1195

Vancouver

Kim KH, Hwang S, Kim MK, Park KU, Yun T, Lee KW, et al. Differential Efficacy of Alpelisib by PIK3CA Mutation Site in Head and Neck Squamous Cell Carcinoma: An Analysis from the KCSG HN 15-16 TRIUMPH Trial. Cancer Research and Treatment. 2025;57(4):968-980. doi:10.4143/crt.2024.1195

BibTeX
@article{Kim2025,
  author = {Kim, Kyoo Hyun and Hwang, Shinwon and Kim, Min Kyoung and Park, Keon-Uk and Yun, Tak and Lee, Keun-Wook and Kim, Joo Hang and Keam, Bhumsuk and Cho, Byoung Chul and Oh, So Yeon and Cho, Sang Hee and Kim, Sangwoo and Kim, Sung-Bae and Hong, Min Hee and Kim, Hye Ryun},
  title = {Differential Efficacy of Alpelisib by PIK3CA Mutation Site in Head and Neck Squamous Cell Carcinoma: An Analysis from the KCSG HN 15-16 TRIUMPH Trial},
  journal = {Cancer Research and Treatment},
  year = {2025},
  volume = {57},
  number = {4},
  pages = {968--980},
  doi = {10.4143/crt.2024.1195}
}
Kostenlos starten →